Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 15, 2008. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding changes in their interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share transactions and does not contain financial performance data.
Material Changes
The filing details changes in shareholdings for five individuals resulting from the purchase of ordinary shares on July 10, 2008. These purchases were executed via a Single Company ISA through the reinvestment of dividends at a price of £12.33 per share. The specific changes are:
- Mr A P Witty: 5 shares
- Mr J S Heslop: 6 shares
- Mr S M Bicknell: 30 shares
- Mr E J Gray: 6 shares
- Mr D S Redfern: 6 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly adheres to the requirements of Disclosure and Transparency Rule 3.1.4R(1)(a) regarding director share transactions.
Key Facts for Investor Verification
- Transaction Date: July 10, 2008
- Share Price: £12.33 per ordinary share
- Transaction Mechanism: Dividend reinvestment via Single Company ISA
- Notification Date: July 15, 2008
- Signatory: Victoria Whyte, Deputy Company Secretary